Current pharmacological treatment of idiopathic inflammatory myopathies. Issue 4 (2nd April 2016)

• Record Type: Journal Article
• Authors: Fasano, Serena; Alves, Sara Custódio; Isenberg, David A.
• Is Part Of: Expert review of clinical pharmacology. Volume 9:Issue 4(2016)
• Page Start: 547
• Page End: 558
• Publication Date: 2016-04-02
• Subjects: Idiopathic inflammatory myopathy -- treatment -- dermatomyositis -- polymyositis -- inclusion body myositis; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1586/17512433.2016.1136561
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features. Although idiopathic inflammatory myopathies share some similarities, different subtypes may have variable responses to therapy, so it is very important to distinguish the correct subtype. There are few randomised, double blind placebo controlled studies to support the current treatment. High dose corticosteroids continue to be the first-line therapy and other immunosupressive drugs are used in refractory cases, as well as steroid-sparing agents. Some novel therapeutic approaches have emerged as potential treatment including tacrolimus, intravenous immunoglobulin and rituximab, following good outcomes reported in case studies. However, more randomised controlled trials are needed. This review considers the current and the potential future therapies for inflammatory myopathies.